Cancer immunotherapy: Moving beyond current vaccines

Nature Medicine

Volumn 10, Issue 9, 2004, Pages 909-915

  Rosenberg, Steven A ^a   Yang, James C ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MELAN A; MONOPHENOL MONOOXYGENASE; PROSTATE SPECIFIC ANTIGEN; RAS PROTEIN; TELOMERASE;

CANCER; CANCER CELL DESTRUCTION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADOLESCENT; ADULT; AGED; CANCER VACCINES; CHILD; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 4644324025     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1100     Document Type: Review

References (74)

1. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001).
2. Ridgway, D. The first 1000 dendritic cell vaccines. Cancer Invest. 21, 876-886 (2003).
3. Ribas, A., Butterfield, L.H., Glaspy, J.A. & Economou, J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21, 2415-2432 (2003).
4. + T cells. J. Exp. Med. 198, 569-580 (2003).
5. Dudley, M.E. et al. Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes. Science 298, 850-854 (2002).
6. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
7. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer. Inst. 92, 205-216 (2000).
8. James, K. et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J. Natl. Cancer Inst. 91, 523-528 (1999).
9. Eberlein, T.J., Rosenstein, M. & Rosenberg, S.A. Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells. Transp. Proc. 15, 396-398 (1983).
10. + T cell adoptive immunotherapy. Immunity 13, 265-277 (2000).
11. + T Cells. Cancer Res. 62, 3459-3465 (2002).
12. Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37-44 (1997).
13. Salgaller, M.L., Marincola, F.M., Cormier, J.N. & Rosenberg, S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749-4757 (1996).
14. Kammula, S.A., Marincola, F.M. & Rosenberg, S.A. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92, 1336-1344 (2000).
15. Phan, G.Q. et al. Immunization of patients with metastatic melanoma using both class I and class II restricted peptides from melanoma-associated antigens. J. Immunother. 26, 349-356 (2003).
16. Panelli, M.C. et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23, 487-498 (2000).
17. + tumors. Cancer Res. 58, 4902-4908(1998).
18. Rosenberg, S.A. et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894-1900 (1998).
19. Rosenberg, S.A. et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163, 1690-1695 (1999).
20. Rosenberg, S.A. et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9, 2973-2980 (2003).
21. Rosenberg, S.A. et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther. 14, 709-714 (2003).
22. Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced staged IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
23. Stift, A. et al. Dendritic cell-based vaccination in solid tumor. J. Clin. Oncol. 21, 135-142 (2003).
24. Schriber, H. Tumor Immunology, in Fundamental Immunology (ed. Paul, W.E.) 1557-1592 (Lippincott Williams & Wilkins, Philadelphia, USA, 2003).
25. Speiser, D.E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645-653 (1997).
26. Marincola, F.M., Jaffee, E.M., Hicklin, D.J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
27. + T cells. Proc. Natl. Acad. Sci. USA 101, 1969-1974 (2004).
28. Von Mehren, M. et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181-1191 (2001).
29. Eder, J.P. et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638 (2000).
30. Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327 (1998).
31. Dudley, M.E. et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24, 363-373 (2001).
32. Timmerman, J.M. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526 (2002).
33. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & and Toda, M. Immunological self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chain (CD25) - Breakdown of a single mechanism of self-tolerance causes various autoimmune-diseases. J. Immunol. 155, 1151-1161 (1995).
34. Hori, S., Takahashi, T. & Sakaguchi, K. Control of autoimmunity by naturally arising regulatory CD4 cells. Adv. Immunol. 81, 331-371 (2003).
35. + suppressor T cell. Immunol. Rev. 182, 58-67 (2001).
36. Morton, D.L. et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 482 (1992).
37. 180-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7, 3012-3024 (2001).
38. Mazzaferro, V. et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9, 3235-3245 (2003).
39. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
40. Waldmann, T.A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
41. Hodge, J.W. et al. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 19, 3552-3567 (2001).
42. Phan, G.Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100, 8372-8377 (2003).
43. Scheibenbogen, C. et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23, 275-281 (2000).
44. Slingluff, C.L. et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21, 4016-4026 (2003).
45. Cebon, J. et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3, 7 (2003).
46. Noguchi, M. et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57, 80-92 (2003).
47. Peterson, A.C., Harlin, H. & Gajewski, T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21, 2342-2348 (2003).
48. + T lymphocytes. Clin. Cancer Res. 10, 828-839 (2004).
49. Van Driel, W.J. et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoa. Eur. J. Cancer 35, 946-952 (1999).
50. Sato, Y. et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer 90, 1334-1342 (2004).
51. + cancers. Proc. Natl. Acad. Sci. USA 97, 12198-12203 (2000).
52. Khleif, S.N. et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. 22, 155-165 (1999).
53. Tanaka, S. et al. Peptides vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J. Immunother. 26, 357-366 (2003).
54. Gulley, J. et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53, 109-117 (2002).
55. Conry, R.M. et al. Phase 1 trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. 5, 2330-2337 (1999).
56. Horig, H. et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000).
57. Von Mehren, M. et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228 (2000).
58. Marshall, J.L. et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332-337 (1999).
59. Marshall, J.L. et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti- carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3973 (2000).
60. Soiffer, R. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95, 13141-13146 (1998).
61. Mitchell, M.S. et al. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin. Cancer Res. 10, 76-83 (2004).
62. Salgia, R. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
63. Neumunaitis, J. et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. 96, 326-331 (2004).
64. Dols, A. et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2 matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum. Gene Ther. 14, 1117-1123 (2003).
65. + progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
66. Mersey, P. et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. 53, 125-134 (2003).
67. Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
68. Schuler-Thurner, B. et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288 (2002).
69. Geiger, J.D. et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61, 8513-8519 (2001).
70. Su, Z. et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63, 2128-2133 (2003).
71. Pong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809-8814 (2001).
72. Holtl, L. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8, 3369-3376 (2002).
73. Belli, F. et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologie findings. J. Clin. Oncol. 20, 4169-4180 (2002).
74. Janetzki, S. et al. Immunization of cancer patients with autologous cancer-derived heat schock protein gp96 preparations: a pilot study. Int. J. Cancer 88, 232-238 (2000).